||5R03CA216174-02 Interpret this number
||University Of Utah
||Statewide Assessment of HPV Vaccination Among Childhood Cancer Survivors
Survivors of childhood and young adult cancer have a substantial risk of developing a second cancer, including
Human Papillomavirus (HPV)-related cancers. Female childhood cancer survivors have 40% relative excess
and male survivors have 150% relative excess of HPV-associated malignancies compared to the general
population. Since 2009, the Children’s Oncology Group guidelines have recommended HPV vaccination to
reduce the risk for HPV-related cancers for all eligible childhood cancer survivors. The limited research to date
demonstrates low uptake and completion of the 3-dose HPV vaccination series among survivors of childhood
cancer. However, these studies have been focused on self-report assessments at single institutions among
female survivors. Evaluating HPV vaccination among survivors in Utah is of great public health importance as
Utah’s 3-dose HPV vaccine series completion is among the lowest in the nation for both female teens (49th
state) and male teens (43rd state). As many survivors of childhood cancer do not expeditiously transition back
to primary care at the end of their cancer treatment, it is likely that their rates of HPV vaccination completion
are even lower than the general population. We propose the first statewide assessment of HPV vaccination
among both female and male childhood cancer survivors and an age and sex-matched general population
comparison group from a largely rural state with low rates of HPV vaccination over a nine year time period
(2006-2015). Building on two statewide resources 1) the Utah Population Database, which is linked to clinical
data from Intermountain Healthcare, including Primary Children’s Hospital, where the majority of pediatric
cancers in Utah are treated, and the 2) Utah Statewide Immunization Information System, we will conduct the
first statewide evaluation of the rate of HPV vaccination among a sample of 1,863 childhood cancer survivors.
Using UPDB allows us to generate an age and sex-matched general population comparison group without
cancer to compare to the survivors. Our outcomes of interest are HPV vaccination initiation, receipt of 2 doses,
3-dose completion, and missed opportunities (defined as a healthcare visit when a patient received at least
one immunization, but not a HPV vaccine dose). In the first aim, we will compare HPV vaccination among
survivors of childhood cancer with the general population. In the second aim, we will identify high-risk groups of
survivors of childhood cancer, such as survivors who are Hispanic, publically-insured, rural, and living in a
health professional shortage area, who may be more likely to forego the HPV vaccine. At the end of the study,
we will have identified whether both male and female childhood cancer survivors are less likely to get the HPV
vaccine compared to adolescents and young adults without cancer. Also, we will establish at statewide level
whether certain childhood cancer survivors (e.g., Hispanic) are more likely to miss getting the HPV vaccine,
which is essential information to developing cancer prevention strategies for this growing population.
HPV Vaccine Experiences and Preferences Among Young Adult Cancer Survivors and Caregivers of Childhood Cancer Survivors.
, Mann K.
, Vaca Lopez P.L.
, Kepka D.
, Wu Y.P.
, Kirchhoff A.C.
Journal of cancer education : the official journal of the American Association for Cancer Education, 2021-03-19; , .